Signal Advisors Wealth LLC Acquires 187 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Signal Advisors Wealth LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,210 shares of the medical research company’s stock after purchasing an additional 187 shares during the period. Signal Advisors Wealth LLC’s holdings in Thermo Fisher Scientific were worth $630,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. WINTON GROUP Ltd purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth $332,000. One Capital Management LLC boosted its stake in Thermo Fisher Scientific by 154.1% in the 2nd quarter. One Capital Management LLC now owns 2,343 shares of the medical research company’s stock worth $1,296,000 after purchasing an additional 1,421 shares in the last quarter. WealthPLAN Partners LLC increased its stake in Thermo Fisher Scientific by 6.5% during the 2nd quarter. WealthPLAN Partners LLC now owns 4,120 shares of the medical research company’s stock valued at $2,279,000 after purchasing an additional 253 shares in the last quarter. Lmcg Investments LLC raised its holdings in Thermo Fisher Scientific by 2.9% in the second quarter. Lmcg Investments LLC now owns 14,382 shares of the medical research company’s stock worth $7,953,000 after buying an additional 400 shares during the last quarter. Finally, Moors & Cabot Inc. grew its holdings in shares of Thermo Fisher Scientific by 1.7% during the second quarter. Moors & Cabot Inc. now owns 3,927 shares of the medical research company’s stock valued at $2,172,000 after buying an additional 67 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. The trade was a 1.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock worth $25,954,465 over the last quarter. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $557.49 on Wednesday. The firm’s 50 day simple moving average is $529.85 and its two-hundred day simple moving average is $568.13. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company has a market capitalization of $213.24 billion, a P/E ratio of 34.95, a P/E/G ratio of 3.54 and a beta of 0.76. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same quarter in the prior year, the firm posted $5.69 EPS. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. Research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase program on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is 9.78%.

Analysts Set New Price Targets

Several research firms recently issued reports on TMO. Bernstein Bank upped their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research report on Tuesday, October 22nd. TD Cowen upped their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Royal Bank of Canada decreased their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a report on Friday, January 10th. Finally, Barclays lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Four analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $648.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.